Simvastatin reduces high uric acid-induced oxidative stress and inflammatory response in vascular endothelial cells via nuclear factor E2-related factor 2 (Nrf2) signaling

Document Type : Original Article


1 Department of Traditional Chinese Medicine and Rheumatism Immunology, The First Affiliated Hospital of Army Medical University, Chongqing 400038, P.R.China

2 Traditional Chinese Medicine Department, The People’s Hospital of Dadukou District Chongqing, Chongqing, 400084, P.R. China


Objective(s): Increased oxidative stress and inflammatory response are risk factors for kidney and cardiovascular diseases in patients with hyperuricemia. Uric acid (UA) has been reported to cause inflammation and oxidative damage in cells by inhibiting the nuclear factor E2-related factor 2 (Nrf2) pathway. Notably, Simvastatin (SIM) can regulate the Nrf2 pathway, but whether SIM can regulate inflammatory response and oxidative stress in vascular endothelial cells induced by high UA via this pathway has not been clarified.
Materials and Methods: To demonstrate this speculation, cell activity, as well as apoptosis, was estimated employing CCK-8 and TUNEL, respectively. Indicators of oxidative stress and inflammation were assessed by related kits and western blotting. Subsequently, the effects of SIM on signaling pathways were examined using western blotting.
Results: The result showed that after UA exposure, oxidative stress was activated and inflammation was increased, and SIM could reverse this trend. Meanwhile, SIM could inhibit high UA-induced apoptosis. In addition, western blotting results showed that SIM reversed the down-regulation of the expression of Nrf2 pathway-related proteins caused by high UA.
Conclusion: SIM alleviated the inflammatory response as well as inhibiting oxidative stress through the Nrf2 pathway, thereby attenuating high UA-induced vascular endothelial cell injury.


Main Subjects

1. Jin M, Yang F, Yang I, Yin Y, Jun Leo J, Wang H, et al. Uric acid, hyperuricemia and vascular diseases. Front Biosci (Landmark Ed)2012; 17:656-69.
2. Zhang S, Wang Y, Cheng J, Haungfu N, Zhao R, Xu Z, et al. Hyperuricemia and cardiovascular disease. Curr Pharm Des 2019; 25:700-709.
3. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol 2014; 26:186-191.
4. Su HY, Yang C, Liang D, Liu HF. Research advances in the mechanisms of hyperuricemia-induced renal injury. Biomed Res Int 2020; 2020:1-12.
5. Kimura Y, Yanagida T, Onda A, Tsukui D, Hosoyamada M, Kono H. Soluble uric acid promotes atherosclerosis via AMPK (AMP-activated protein kinase)-mediated inflammation. Arterioscler Thromb Vasc Biol 2020; 40:570-582.
6. Zhou Y, Zhao M, Pu Z, Xu G, Li X. Relationship between oxidative stress and inflammation in hyperuricemia: analysis based on asymptomatic young patients with primary hyperuricemia. Medicine (Baltimore) 2018; 97:49-57.
7. Tomiyama H, Shiina K, Vlachopoulos C, Iwasaki Y, Matsumoto C, Kimura K, et al. Involvement of arterial stiffness and inflammation in hyperuricemia-related development of hypertension. Hypertension 2018; 72:739-745.
8. Pedersen TR, Tobert JA. Simvastatin: a review. Expert Opin Pharmacother 2004; 5:2583-2596.
9. Psarros C, Economou EK, Koutsilieris M, Antoniades  C. Statins as pleiotropic modifiers of vascular oxidative stress and inflammation. J Crit Care Med (Targu Mures)2015; 1:43-54.
10. Al-Rasheed NM, Al-Rasheed NM, Hasan IH, Al-Amin AM, Al-Ajmi HN, Mohamad RA,  et al. Simvastatin ameliorates diabetic cardiomyopathy by attenuating oxidative stress and inflammation in rats. Oxid Med Cell Longev 2017; 2017:1-13.
11. Tulbah AS, Pisano E, Landh E, Scalia S, Young PM, Traini D, et al. Simvastatin nanoparticles reduce inflammation in LPS-stimulated alveolar macrophages. J Pharm Sci 2019; 108:3890-3897.
12. Zhang CY, Ren XM, Li HB,  Wei W, Wang KX, Li YM, et al. Simvastatin alleviates inflammation and oxidative stress in rats with cerebral hemorrhage through Nrf2-ARE signaling pathway. Eur Rev Med Pharmacol Sci 2019; 23:6321-6329.
13. Sivandzade F, Prasad S, Bhalerao A, Cucullo L. NRF2 and NF-B interplay in cerebrovascular and neurodegenerative disorders: molecular mechanisms and possible therapeutic approaches. Redox Biol 2019; 21:1-16.
14. Ahmed SM, Luo L, Namani A, Wang XJ, Tang X. Nrf2 signaling pathway: pivotal roles in inflammation. Biochim Biophys Acta Mol Basis Dis 2017; 1863:585-597.
15. Zhang X, Yu Y, Lei H, Cai Y, Shen J, Zhu P, et al. The Nrf-2/HO-1 signaling axis: a ray of hope in cardiovascular diseases. Cardiol Res Pract 2020; 2020:1-9.
16. Singh A, Venkannagari S, Oh KH, Zhang YQ, Rohde JM, Liu L, et al. Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors. ACS Chem Biol 2016; 11:3214-3225.
17. Song Q, Peng S, Sun Z, Heng X, Zhu X. Temozolomide drives ferroptosis via a DMT1-dependent pathway in glioblastoma cells. Yonsei Med J 2021; 62:843-849.
18. Shao Z, Wang B, Shi Y, Xie C, Haung C, Chen B, et al. Senolytic agent quercetin ameliorates intervertebral disc degeneration via the Nrf2/NF-kappaB axis. Osteoarthritis Cartilage 2021; 29:413-422.
19. Zhou MQ, Jin E, Wu J, Ren F, Yang YZ, Duan DD, et al. CTRP12 ameliorated lipopolysaccharide-induced cardiomyocyte injury. Chem Pharm Bull (Tokyo)2020; 68:133-139.
20. Hong Q, Wang L, Huang Z, Feng Z, Ciu S, Fu B, et al. High concentrations of uric acid and angiotensin II act additively to produce endothelial injury. Mediators Inflamm 2020; 2020:1-11.
21. Durackova Z. Some current insights into oxidative stress. Physiol Res 2010; 59:459-469.
22. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells -- implications in cardiovascular disease. Braz J Med Biol Res 2004; 37:1263-1273.
23. Rendra E, Riabov V, Mossel DM, Sevastyanova T, Harmsen MC, Kzhyshkowska J. Reactive oxygen species (ROS) in macrophage activation and function in diabetes. Immunobiology 2019; 224:242-253.
24. Lee CH, Huang CW, Chang PC, Shiau JP, Lin IP, Lin MY, et al. Reactive oxygen species mediate the chemopreventive effects of syringin in breast cancer cells. Phytomedicine 2019; 61:152844-1528.
25. Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic Res 2010; 44:479-496.
26. Rodic S, Vincent MD. Reactive oxygen species (ROS) are a key determinant of cancer’s metabolic phenotype. Int J Cancer 2018; 142:440-448.
27. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal 2014; 20:1126-1167.
28. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010; 49:1603-1616.
29. Ambrozova N, Ulrichova J, Galandakova A. Models for the study of skin wound healing. The role of Nrf2 and NF-kappaB. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2017; 161:1-13.
30. Shaw P, Chattopadhyay A. Nrf2-ARE signaling in cellular protection: mechanism of action and the regulatory mechanisms. J Cell Physiol 2020; 235:3119-3130.
31. Dera AA, Rajagopalan P, Alfhili MA, Ahmed I, Chandramoorthy HC. Thymoquinone attenuates oxidative stress of kidney mitochondria and exerts nephroprotective effects in oxonic acid-induced hyperuricemia rats. Biofactors 2020; 46:292-300.
32. Chang Y, Li S, Guo W, Yang Y, Zhang W, Zhang Q, et al. Simvastatin protects human melanocytes from H2O2-induced oxidative stress by activating Nrf2. J Invest Dermatol 2017; 137:1286-1296.
33. Zhang Y, Rong S, Feng Y, Zhao L, Hong J, Wang R, et al. Simvastatin attenuates renal ischemia/reperfusion injury from oxidative stress via targeting Nrf2/HO-1 pathway. Exp Ther Med 2017; 14:4460-4466.